Objectives: The overall study aim was to identify the relevant preclinical teicoplanin pharmacokinetic (PK)/pharmacodynamic (PD) indices to predict efficacy and suppression of resistance in MRSA infection.
Introduction
Teicoplanin is a glycopeptide with a similar spectrum of antibacterial activity to vancomycin. 1, 2 Teicoplanin is licensed in the EU and other countries for the treatment of moderate to severe methicillin-resistant Gram-positive infections in children and adults. 1 Teicoplanin was developed before contemporary pharmacokinetic (PK)/pharmacodynamic (PD) techniques and there is little PD information that provides a rationale for the optimal use of this agent.
Drug exposure targets that are associated with a high probability of a successful clinical outcome are relatively poorly defined. Initial regimens were designed to achieve a C min of 10 mg/L. 3 More recently, this drug exposure target has been increased to .15 mg/L for the majority of clinical indications (e.g. bacteraemia, pneumonia, complicated skin and soft-tissue infections). Higher targets of 20 and 30-40 mg/L are now advocated for the treatment of bone/joint infections and infective endocarditis, respectively. 1 These updated targets are based on small retrospective studies in adults. 4, 5 Herein, we describe the PD of teicoplanin against MRSA. We used a well-characterized hollow-fibre infection model (HFIM) and a murine thigh infection model of MRSA to establish these relationships. We considered both the antibacterial effect of teicoplanin and the emergence of resistance to teicoplanin as primary study endpoints. We evaluated the relevant PK/PD indices that best describe the killing of susceptible subpopulations and suppress emergence of resistance. We finally bridged the experimental results to patients to reflect on the adequacy of current EUCAST in vitro susceptibility breakpoints.
Materials and methods
Organism, susceptibility studies and mutational frequency
MRSA ATCC
V R 43300 TM (ATCC V R , Middlesex, UK) was used for all experiments. The isolate was stored on beads at #80 C. The MIC for the strain was determined using the EUCAST broth microdilution methodology on three separate occasions. 6 The mutational frequency of a subpopulation with MIC !8 mg/L was determined using teicoplanin-containing Mueller-Hinton (MH) agar (Sigma-Aldrich, Dorset, UK), as previously reported. 7 
Bioanalytical methodology
Concentrations of teicoplanin were measured using a commercially available fluorescence polarization immunoassay (FPIA; Thermo Fisher Scientific, Germany). This is a homogeneous particle-enhanced turbidimetric immunoassay that utilizes Quantitative Microsphere System (QMS) technology and was implemented on an automated analyser (Abbott Architect ci4100). A concentration-dependent agglutination inhibition curve was obtained with minimum and maximum rates of agglutination at the highest and lowest teicoplanin concentrations, respectively. The limit of quantification (LOQ) was ,3.0 mg/L. The dynamic range was 3-100 mg/L and overall (intra and inter-day) precision was ,6%.
In vitro model of MRSA infection in a hollow-fibre system
Teicoplanin for intravenous infusion (Targocid 400 mg, Sanofi Aventis, Surrey, UK) was used for all experiments. A paediatric PK profile was simulated in the HFIM. An elimination half-life of 6.4 h for teicoplanin was targeted in all the experiments, which was based on a median clearance estimate from a previous population PK model in children. 8 For each experiment, fresh bacterial isolates were grown on blood agar (Oxoid Ltd, Hants, UK) and incubated at 37 C for 24 h. Bacteria were then inoculated into the extra-capillary space of each hollow-fibre cartridge. The desired starting inoculum ($6 log 10 cfu/mL) was confirmed by quantitative culture on MH agar plates (Thermo Fisher Scientific, Runcorn, UK). The HFIM was incubated at 37 C in ambient air.
In vitro PK and PD studies
Initial dose-finding studies were conducted using concentration-time profiles of teicoplanin corresponding to human dosages of 10-100 mg/kg/day. Dosages that encompassed the exposure-response relationships for bacterial killing and the emergence of resistance were defined in preliminary experiments. The current standard dosing for teicoplanin in adults is three loading doses of 400 mg ($6 mg/kg) 12 hourly, followed by a maintenance dose of 400 mg/day. In contrast, children receive three loading doses of 10 mg/kg 12 hourly, followed by a maintenance dose of 10 mg/kg daily.
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A total daily dose of 10 and 30 mg/kg/day of teicoplanin was administered in the following ways: (i) a bolus administered every 24 h; (ii) two half dosages administered every 12 h; and (iii) the total daily dose infused over a 24 h period [continuous infusion (CI)]. Treatment was initiated 24 h postinoculation and the experiments were conducted for 7 days to simulate the typical duration of clinical therapy and provide the opportunity to observe the emergence of antimicrobial resistance. Five experiments were conducted and each experiment contained six study arms (one control drugfree arm and five teicoplanin-treated arms).
In vitro PK studies PK samples (1 mL) were withdrawn from the central compartment of the HFIM before each dose and at 1, 3, 6, 12 and 24 h. Sampling occurred during the first dose interval and at day 6 of therapy. The teicoplanin AUC 0-24 , maximum concentration (C max or peak) and minimum (C min ) teicoplanin concentrations at steady state (144-168 h) were calculated from the Bayesian posterior estimates for the PK parameter values from each hollow-fibre cartridge (see below).
In vitro PD studies
Bacterial samples (1 mL) were withdrawn from the extra-capillary space of each hollow-fibre cartridge and 10-fold serial dilutions (100 lL) were plated onto both drug-free and drug-containing agar plates. Sampling occurred at 0, 2, 6 and 24 h post-infection and every 24 h thereafter (immediately prior to dosing). Total and resistant subpopulations were quantified. The LOQ was 10 cfu/mL (1 log 10 cfu/mL). To investigate whether the mutants that grew on drug-containing plates had an elevated MIC, $10 colonies were selected from each plate and the MIC was re-estimated as previously described.
PK and PD studies in a murine thigh infection model
A well-characterized neutropenic murine thigh infection model was used to provide a complementary perspective on the PD of teicoplanin to that provided by the HFIM. All experiments were conducted under UK Home Office project license PPL 40/3630 and approved by the University of Liverpool's Animal Welfare and Ethics Review Board. The mice were housed in vented HEPA-filtered cages, and food and water were provided ad libitum.
Male CD1 mice (20-30 g) were rendered neutropenic on days #4 and #1 with the intraperitoneal administration of cyclophosphamide (Baxter, Liverpool, UK) using 150 and 100 mg/kg, respectively. 9 Each experiment comprised a control arm and three cohorts of mice receiving teicoplanin. At time=zero mice were inoculated with 2%10 6 cfu/mL MRSA (43300) in each posterior thigh muscle in a 50 lL volume. Teicoplanin was commenced 2 h post-infection and was administered intravenously every 12 h.
In vivo PK studies
Groups of mice (n " 9 per dosage cohort) received dosages of 2.5, 15 and 100 mg/kg/day (as multiple 12-hourly intravenous dosages) that were chosen to investigate the total bactericidal effect and the suppression of resistance based on preliminary dose-finding studies. PK sampling was performed at 0, 0.5, 1, 2, 4 and 12 h post-dose. Three mice were used per dose timepoint. Samples were immediately centrifuged and plasma was stored at #80 C until analysis.
In vivo PD studies
At the time of sacrifice (at 2, 14 and 26 h post-infection) both thighs were aseptically removed and placed in separate culture tubes with 2 mL of PBS. Samples were individually homogenized using a Polytron disperser (VDI 12, VWR, Lutterworth, UK). Aliquots of 100 lL from 10-fold serial dilutions were plated onto drug-free MH agar and MH agar containing 8 mg/L teicoplanin. The mean value of the bacterial burden from the left and right thighs from each mouse was determined. The mean and SD for a group of three mice was then calculated.
PK/PD mathematical modelling
A mathematical model was fitted to the experimental data from the HFIM and mice. The population PK program Pmetrics was used for all fitting (v. The structural model took the form:
Equation (1) describes the rate of change of the amount of teicoplanin (mg) in the central compartment (X1). Equations (2) and (3) describe the rate of change of burden of a susceptible bacteria population (S) and a resistant/ mutant (R) bacteria population in the HFIM/murine model. The rate of growth is a balance between bacterial growth and death. POPmax (cfu/mL) is the theoretical maximum bacterial density; KgmaxS/R (log 10 cfu/mL/h) is the maximum rate of bacterial growth in both subpopulations; KkmaxS/R (log 10 cfu/mL/h) is the rate of bacterial killing induced by teicoplanin; C50S/R (mg/L) represents the teicoplanin drug concentrations that produce half-maximal killing in both subpopulations; HS and HR are the respective slope functions. There were three output equations for the model: (i) Y(1) " X(1)/V, which described the time course of teicoplanin concentrations; (ii) Y(2) " DLOG10[X(2) ! X(3)], which described the time course of the total population; and (iii) Y(3) " DLOG10[X(3)], which described the time course of the resistant subpopulation.
The goodness of fit of each model to the data was assessed using a combination of the following: (i) the log-likelihood value; (ii) the Akaike information criterion (AIC); (iii) the coefficient of determination (r 2 ) from the linear regression of the observed-predicted plots before and after the Bayesian step; and (iv) a minimization of bias and imprecision values of the observed-predicted plots.
Exposure-effect relationships and optimal targets
To determine the PK/PD index that best described bacterial killing and the suppression of drug resistance, scatter plots from the in vitro dose-fractionation studies were constructed that related the fAUC/MIC, fC max /MIC and fC min /MIC with both the observed antibacterial effect and the emergence of a drug-resistant subpopulation from the HFIM. The relevant PK/PD index was then further explored with the in vivo mouse data. A non-linear regression model was fitted to the data using Prism software (GraphPad Software Inc., La Jolla, CA, USA). The coefficient of determination and visual examination of the fit were used to discriminate the various PD indices.
Monte Carlo simulations and probability of target attainment (PTA) analysis
Monte Carlo simulations were performed with Pmetrics. A population of 1000 simulated patients was generated for each teicoplanin regimen. These simulated patients were used to examine the outcomes of candidate regimens of teicoplanin. For the adult simulations we used the population PK estimates and covariance matrix from a previously developed population PK model in adults. 8 For the paediatric simulations, we used the population PK estimates and covariance matrix from a previously developed PK model in children. 35 For children, the weight-based dose of teicoplanin (mg/kg) was administered to each simulated patient as a 3 min intravenous infusion. The weight-based dosage was converted into an absolute dosage for intravenous administration (as would happen at the bedside) by multiplying by the simulated weight (for example, a 20 kg child receiving 10 mg/kg would receive 200 mg of teicoplanin). The following covariate limits were used for the simulations: weight, 9-62.2 kg; age, 1-16 years; and estimated glomerular filtration rate (GFR) (Schwartz), 49-178.1 mL/ min/1.73 m 2 . A variety of candidate regimens were investigated: the standard teicoplanin dosage and regimens 2 and 3, with the same daily maintenance dose but different frequency of dosing (every 24 h versus every 12 h). We considered this relevant to evaluate the impact of frequency on AUC and C min attained drug exposures. Estimation of various drug exposures in terms of AUC 0-24 and C min at steady state (between days 3 and 4 of treatment) was performed for each dosage regimen for both adults and children. The selection of an AUC and C min time frame (72-96 h) is based on current recommendations for therapeutic drug monitoring (TDM). 1 For the PTA analysis, AUC/MIC targets producing stasis and 2 log 10 cell kill in the murine model were used. The distribution of the MRSA MICs determined using EUCAST methodology from 0.032 to 16 mg/L was plotted. 12 Fractional target attainment was calculated for the various regimens.
Results

In vitro susceptibility and mutational frequency
The modal teicoplanin MIC for MRSA ATCC 43300 was 0.5 mg/L. The strain was oxacillin resistant by Etest (Oxoid). The mutational frequency (at 16 % MIC) was 1.02%10
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. MICs for resistant mutants at the end of in vitro experiments (168 h) were up to five 2-fold dilutions higher (2 to !16 mg/L).
PD of teicoplanin against MRSA: dose-finding studies and dose fractionation studies in the HFIM
There was a dose-dependent decline in the total bacterial density following exposure to teicoplanin. Total bactericidal effect was achieved with dosages of !10 mg/kg/day and suppression of resistance with dosages !30 mg/kg/day.
The results from the dose fractionation studies are shown in Figure 1 . Non-linear regression analysis showed a strong correlation between fC max /MIC, fAUC/MIC and fC min /MIC and bacterial killing (r 2 " 0.92, 0.9 and 0.86, respectively). There was also a strong association between fC max /MIC and fAUC/MIC and suppression of teicoplanin resistance (r 2 " 0.79 and 0.95, respectively). In contrast, a weaker relationship was apparent between fC min /MIC and suppression of teicoplanin resistance (r 2 " 0.45).
Murine MRSA thigh infection model
There was a dose-dependent decline in total bacterial density in the thighs of mice treated with teicoplanin. Teicoplanin was bactericidal (!2 log 10 cell kill) for all regimens. There was emergence of a resistant subpopulation with all regimens investigated, with the appearance of an inverted U (Figure 2 ).
PK/PD mathematical modelling
There was a good fit of the model to the PK/PD data. For the in vitro model, the linear regression of observed versus predicted values before and after the Bayesian step had an r 2 value of: (i) 0.83 and 0.9, respectively, for the PK data; (ii) 0.55 and 0.7, respectively, for the PD data related to the total population; and (iii) 0.6 and 0.7, respectively, for the PD data related to the resistant bacterial population. For the in vivo model, the linear regression of the observedpredicted values for the population and for the Bayesian posterior had an r 2 value of: (i) 0.87 and 0.99, respectively; (ii) 0.94 and 0.95
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respectively. and (iii) 0.47 and 0.63, respectively (all with minimal bias and imprecision). The population PK/PD parameter estimates from the HFIM and the murine thigh model are shown in Table 1 . The estimated t1 =2 of teicoplanin in the HFIM was 8.7 h.
Exposure-effect relationships and optimal targets
In the HFIM, a teicoplanin fAUC/MIC ratio at steady state of !576 was associated with a 2 log 10 cfu/mL decline in bacterial density and !1325 was required to suppress the emergence of resistant clones (Figure 1a) . For the resistance studies, a characteristic inverted U was observed with maximal amplification of resistance with an fAUC/MIC of $400-600 (Figure 1a) .
Based on the HFIM studies (above), the AUC/MIC was used as the dynamically linked index for both effect and the suppression of resistance in the mouse (Figure 2) . A teicoplanin total drug AUC 0-24 /MIC ratio of %88.8 and 610.4 was associated with stasis and near maximal bacterial killing (2 log 10 cell kill), respectively. A total drug AUC 0-24 /MIC ratio !1400-1500 was required for near complete suppression of emergence of resistance. Maximal amplification of resistance was seen with total drug AUC 0-24 /MIC ratios of 500-700 (Figure 2b ). Figure 3 . Calculations of drug exposures simulated at steady state (days 3-4) in terms of AUC 0-24 and C min are shown in Table 2 for each population (adults and children) and dosage regimen simulated.
Discussion
In this study the AUC/MIC ratio was the PD index that best links the administration of teicoplanin with the antibacterial effect and Vc, volume of distribution in the central compartment; Kgmax, maximum rate of bacterial growth; POPmax, theoretical maximum bacterial density; H, Hill function; C50, teicoplanin concentration producing half-maximal bacterial kill; IC, initial condition in bacterial density (1 for the susceptible population and 2 for the resistant population); Kkmax, maximum rate of drug-induced killing. In the murine model, cfu/g corresponds to cfu/mL. S and R correspond to the total susceptible population and the resistant bacterial population, respectively.
Ramos-Martín et al. Pharmacodynamics of teicoplanin against MRSA JAC the suppression of resistance. A total drug AUC/MIC ratio of 88.8 and 610.4 results in stasis and a 2 log 10 cell kill, respectively. A previous study in mice also suggests teicoplanin displays concentration-dependent antibacterial activity, with both C max /MIC and AUC/MIC identified as the relevant PD indices. 13 We demonstrate that all PD targets result in the amplification of resistant mutants (Figure 2) . Thus, the antibacterial effect resulting from clinically relevant drug exposures is always tempered by the emergence of drug resistance, and the two are inextricably related. Higher teicoplanin exposure thresholds (e.g. AUC/MIC %1500) that are predicted to suppress the emergence of resistance are not obtainable using current regimens. The magnitude of drug exposure that produces stasis in immunocompromised mice is relevant for patients with Staphylococcus aureus bacteraemia (oritavancin and linezolid) and complicated skin and skin structure infections (linezolid and tigecycline). [14] [15] [16] [17] [18] [19] A teicoplanin AUC/MIC of 88.8 is likely relevant for patients with skin and skin-structure infections. As can be seen from Figure 3 , such a target is readily achievable for simulated patients receiving currently licensed regimens, with fractional target attainment rates of 84% and 94% in children and adults, respectively. For more serious staphylococcal infections, such as pneumonia, a higher PD target is generally required. 18, 20 An AUC/MIC of 610.4 produces logarithmic bacterial killing in mice. This estimate is consistent with several retrospective clinical studies in which teicoplanin AUCs !750-800 mgÁh/L and AUC/MIC !900 are associated with favourable clinical outcomes in adults with serious MRSA infections. [21] [22] [23] A higher AUC/MIC ratio is also consistent with the recent upward revision in target C min concentrations recommended in the Summary of Product Characteristics for the treatment of patients with deep-seated staphylococcal infections. 1 The administration of a fixed teicoplanin regimen is reasonable for skin and skin structure infections. Standard teicoplanin therapy results in target attainment in a majority of patients and the WT population can be largely covered. In contrast, more serious infections that require higher drug exposures require routine TDM. Too few patients receiving a fixed regimen achieve an adequate AUC/MIC of 610.4 and are at risk of concentration-dependent therapeutic failure. For these patients, drug measurement and dosage adjustment is required. An alternative strategy is the use of combination chemotherapy. There is a large amount of preclinical data that have explored the potential benefits of combining glycopeptides with rifampicin, fosfomycin and b-lactams. [24] [25] [26] [27] [28] These ideas are being studied in several prospective clinical trials. ARREST (ISRCTN 37666216) is evaluating the potential benefit of adjunctive rifampicin in S. aureus bacteraemia, 29 and CAMERA-2 (NCT02365493) is investigating the combination of glycopeptides with b-lactams to treat hospitalized patients with MRSA bacteraemia. 30 Monte Carlo simulations and the PTA analysis suggest that patients infected with strains at the upper end of the WT distribution may be difficult to treat. This appears to be the case even if a stasis endpoint is used. The ECOFF using EUCAST methodology is 2 mg/L. 12 At this MIC, only 60% and 70% of children and adults, respectively, receiving a standard regimen are predicted to achieve a stasis target. This is strong evidence to consider a reduction in the breakpoint by at least a dilution to 1 mg/L. 31 For more serious infections that require higher PD targets the situation is worse and the breakpoint divides the WT population.
We acknowledge that only a single strain was studied in the murine model and HFIM. Nevertheless, two experimental models were used that yielded complementary information and allowed us to exploit the respective strengths of each. The murine thigh model is well characterized, has the advantage of simulating protein binding and is a mimic of complicated skin and skin-structure infections, which are common clinical problems. Protein binding in mice is similar to that in humans ($90%). 3, 32 However, the relevance of protein binding for teicoplanin warrants further study. Many factors may influence the degree of protein binding in vivo, such as disease status, drug concentration, types of circulating proteins and the interaction with other drugs. 33 The HFIM enabled us to explore the PD of resistance suppression. Specifically, it allows the use of a higher inoculum and a longer duration of therapy, which are both difficult to achieve in animal models of infection. The high inoculum, relatively longer delay in initiation of therapy and longer duration of treatment could all have resulted in higher estimates of drug exposure for achieving the same antibacterial activity in the HFIM compared with the murine model. 34 In summary, the findings from these two model systems and PD analyses suggest that teicoplanin should be used with some caution for the treatment of strains with MICs at the upper edge of the WT population. TDM is a requirement for the treatment of serious infections to minimize the probability of concentrationdependent therapeutic failure.
